Sales and Marketing

Showing 15 posts of 11528 posts found.

Cancer drugs lift Pfizer in third quarter

October 30, 2013 Sales and Marketing Lipitor, Lyrica, Pfizer, Q3, Xalkori

Pfizer saw a drop in revenue for the third quarter but the future looks bright as new products begin to …

Unpublished trials ‘violates ethical obligation’ to patients

October 30, 2013 Research and Development, Sales and Marketing BMJ, Goldacre, all trials, trials

A new study published in the BMJ has found almost one in three (29%) of large clinical trials remain unpublished …
baali_muganga

Aesica hires business development manager and director

October 30, 2013 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Aesica, muganga

Contract development and manufacturing organisation (CDMO) Aesica has appointed Baali Muganga to the role of east coast US business development …
Gilead image

‘Game-changing’ hep C pill gets FDA panel nod

October 29, 2013 Sales and Marketing FDA, Gilead, hep C, sofosbuvir

Gilead Science’s investigational hepatitis C drug sofosbuvir is one step closer to approval in the US after an FDA advisory …
biogen idec image

Strong sales for Biogen Idec’s MS drug

October 29, 2013 Sales and Marketing Biogen IDEC, Q3, gilenya, tecfidera

Biogen Idec’s oral multiple sclerosis (MS) drug Tecfidera lived up to its blockbuster-in-waiting billing with third quarter sales that exceeded …
brian_mcnamee_amgen

Amgen promotes two senior executives

October 29, 2013 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen

Amgen has promoted two senior executives as Brian McNamee becomes executive vice president and Stuart Tross senior vice president. McNamee …

New online tool to hear lung cancer patients’ stories

October 29, 2013 Medical Communications, Sales and Marketing Boehringer, NSCLC, glcc, lung cancer

The Global Lung Cancer Coalition and Boehringer Ingelheim have teamed-up to increase awareness of the challenges facing individuals and families …
sanofi image

PMCPA: Sanofi ‘discredited pharma’

October 28, 2013 Medical Communications, Sales and Marketing ABPI, PMCPA, Sanofi, breach

Sanofi has lowered the public’s confidence in the pharma industry, according to the PMCPA, which enforces the ABPI Code of …
Actelion image

Positive CHMP verdicts for Actelion and Lundbeck

October 28, 2013 Sales and Marketing Actelion, CHMP, FDA, Lundbeck

Actelion and Lundbeck both took a step closer to EU approval for two drugs seen as pivotal to their future …

Strategic planning: don’t just do it, use it

October 28, 2013 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing MSI, craig, strategic planning

Every year, thousands of pharma employees spend endless hours in meetings discussing, building and presenting brand plans. Countless teams develop …
sanofi pasteur image

Sanofi starts C. diff study

October 28, 2013 Research and Development, Sales and Marketing C diff, Sanofi Pasteur, cdi, clostridium

Sanofi’s vaccines division is beginning a Phase III programme looking at the safety and effectiveness of an investigational treatment for …
dominic_blakemore_shire

Shire hires finance director

October 28, 2013 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Shire, dominic blakemore

Dominic Blakemore will join Shire’s Board from January next year as a non-executive director and member of its Audit, Compliance …

Sharon Hurley

October 25, 2013 Medical Communications, Sales and Marketing Med Comms

Synergy Vision expands client services team to meet demand in UK and Ireland Award-winning medical communications agency Synergy Vision is …
astrazeneca image

Phoenix from Charnwood’s ashes

October 25, 2013 Research and Development, Sales and Marketing AstraZeneca, Charnwood, medilink

The shuttering of AstraZeneca’s R&D site at Charnwood in Leicestershire has had a positive effect on the region’s life sciences …
Lucentis image

NICE ‘yes’ to Lucentis – with price cut

October 25, 2013 Sales and Marketing Dillon, Lucentis, NICE, Novartis

A price cut is the deal-breaking condition attached to NICE’s final draft guidance recommending Lucentis as an option for patients …
The Gateway to Local Adoption Series

Latest content